Funder: ALS Association
Due Dates: August 12, 2025 (Application system opens) | September 23, 2025 (LOI due) | January 13, 2026 (Full application due)
Funding Amounts: Up to $12 million direct costs per project (max 5 years); total available: up to $60 million
Summary: Supports high-quality, patient-centered comparative clinical effectiveness research (CER) projects addressing rare diseases.
Key Information: Strong emphasis on patient/stakeholder engagement and cross-disease research; covers patient care costs within direct cost cap.